查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1417484

血液肿瘤检测市场报告：2030 年趋势、预测与竞争分析

Hemato Oncology Testing Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

血液肿瘤检测的趋势和预测

到 2030 年，全球血液肿瘤检测市场预计将达到 72 亿美元，2024 年至 2030 年复合年增长率为 14.5%。市场的主要驱动力是个人化医疗学术团体数量的增加、血癌盛行率的上升以及私人诊断设施数量的增加。全球血液肿瘤检测市场的未来充满希望，医院和学术/研究机构市场充满机会。

血液肿瘤检测市场洞察

Lucintel 预测，由于大众对各种治疗方案（包括定製药物疗法）的了解不断增加，服务在预测期内将继续占据更大的份额。

由于多发性骨髓瘤、淋巴瘤和白血病的盛行率不断上升，拥有最先进的医疗设施和医疗保健，以及新技术的引进，北美在预测期内可能仍然是最大的地区。

常问问题

Q1.市场规模有多大？

A1. 到 2030 年，全球血液肿瘤检测市场预计将达到 72 亿美元。

Q2.市场成长预测如何？

A2. 2024年至2030年，全球血液肿瘤检测市场预计将以14.5%的复合年增长率成长。

Q3.影响市场成长的主要驱动因素有哪些？

A3. 该市场的主要驱动力是个人化医疗学术会议数量的增加、血癌发病率的上升以及私人诊断设施数量的增加。

Q4.市场的主要细分市场是什么？

A4. 全球血液肿瘤检测市场前景广阔，医院、学术和研究机构市场充满机会。

Q5. 市场上主要企业有哪些？

A5.主要血液肿瘤检测公司如下。

  • F. Hoffmann-La Roche
  • Abbott
  • EntroGen
  • Qiagen
  • Cepheid
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Illumina
  • Amoy Diagnostics
  • ArcherDX

Q6.未来最大的细分市场是什么？

A6.Lucintel 预计，由于大众对各种治疗方案（包括定製药物疗法）的了解不断增加，服务在预测期内仍将占据更大的份额。

Q7. 未来五年预计哪个地区将成为最大的市场？

A7. 由于多发性骨髓瘤、淋巴瘤和白血病盛行率不断上升，拥有最先进的医疗设施和医疗保健，以及新技术的引进，在预测期内，北美将继续成为最大的地区。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球血液肿瘤检测市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球血液肿瘤检测市场趋势（2018-2023）与预测（2024-2030）
  • 按技术分類的全球血液肿瘤检测市场
    • PCR
    • IHC
    • NGS
    • 细胞遗传学
    • 其他的
  • 按癌症类型分類的全球血液肿瘤检测市场
    • 白血病
    • 淋巴瘤
    • 骨髓增生性肿瘤
    • 其他的
  • 按产品分類的全球血液肿瘤检测市场
    • 检测套件和试剂
    • 服务
  • 按最终用途分類的全球血液肿瘤学测试市场
    • 医院
    • 学术研究所
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球血液肿瘤检测市场（按地区）
  • 北美血液肿瘤检测市场
  • 欧洲血液肿瘤检测市场
  • 亚太地区血液肿瘤检测市场
  • 其他地区血液肿瘤检测市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 技术驱动的全球血液肿瘤检测市场成长机会
    • 按癌症类型分類的全球血液肿瘤学测试市场成长机会
    • 全球血液肿瘤检测市场成长机会（按产品）
    • 全球血液肿瘤学测试市场成长机会（按最终用途）
    • 按地区分類的全球血液肿瘤检测市场成长机会
  • 全球血液肿瘤检测市场的新趋势
  • 战略分析
    • 新产品开发
    • 全球血液肿瘤检测市场的产能扩张
    • 全球血液肿瘤检测市场的合併、收购与合资
    • 认证和许可

第七章主要企业概况

  • F. Hoffmann-La Roche
  • Abbott
  • EntroGen
  • Qiagen
  • Cepheid
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Illumina
  • Amoy Diagnostics
  • ArcherDX
简介目录

Hemato Oncology Testing Trends and Forecast

The future of the global hemato oncology testing market looks promising with opportunities in the hospital and academic & research institutes market. The global hemato oncology testing market is expected to reach an estimated $7.2 billion by 2030 with a CAGR of 14.5% from 2024 to 2030. The major drivers for this market are increasing the number of conferences on personalized medicine, rising rate of hematologic cancer, and growing number of privately run diagnostic facilities.

A more than 150-page report is developed to help in your business decisions.

Hemato Oncology Testing by Segment

The study includes a forecast for the global hemato oncology testing by technology, cancer type, product, end use, and region.

Hemato Oncology Testing Market by Technology [Shipment Analysis by Value from 2018 to 2030]:

  • PCR
  • IHC
  • NGS
  • Cytogenetics
  • Others

Hemato Oncology Testing Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

  • Leukemia
  • Lymphoma
  • Myeloproliferative Neoplasms
  • Other

Hemato Oncology Testing Market by Product [Shipment Analysis by Value from 2018 to 2030]:

  • Assay Kits and Reagents
  • Services

Hemato Oncology Testing Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Academic & Research Institutes
  • Others

Hemato Oncology Testing Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Hemato Oncology Testing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies hemato oncology testing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the hemato oncology testing companies profiled in this report include-

  • F. Hoffmann-La Roche
  • Abbott
  • EntroGen
  • Qiagen
  • Cepheid
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Illumina
  • Amoy Diagnostics
  • ArcherDX

Hemato Oncology Testing Market Insights

Lucintel forecasts that service will remain the larger segment over the forecast period due to increasing public knowledge of various treatment options, including tailored medications.

North America will remain the largest region over the forecast period due to the increased prevalence of multiple myeloma, lymphoma, and leukemia, along with the availability of cutting-edge medical facilities and healthcare, as well as the introduction of new technology.

Features of the Global Hemato Oncology Testing Market

Market Size Estimates: Hemato oncology testing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Hemato oncology testing market size by various segments, such as by technology, cancer type, product, end use, and region in terms of value ($B).

Regional Analysis: Hemato oncology testing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different technology, cancer type, product, end use, and regions for the hemato oncology testing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the hemato oncology testing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the hemato oncology testing market size?

Answer: The global hemato oncology testing market is expected to reach an estimated $7.2 billion by 2030.

Q2. What is the growth forecast for hemato oncology testing market?

Answer: The global hemato oncology testing market is expected to grow with a CAGR of 14.5% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the hemato oncology testing market?

Answer: The major drivers for this market are increasing the number of conferences on personalized medicine, rising rate of hematologic cancer, and growing number of privately run diagnostic facilities.

Q4. What are the major segments for hemato oncology testing market?

Answer: The future of the global hemato oncology testing market looks promising with opportunities in the hospital and academic & research institutes market.

Q5. Who are the key hemato oncology testing market companies?

Answer: Some of the key hemato oncology testing companies are as follows.

  • F. Hoffmann-La Roche
  • Abbott
  • EntroGen
  • Qiagen
  • Cepheid
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Illumina
  • Amoy Diagnostics
  • ArcherDX

Q6. Which hemato oncology testing market segment will be the largest in future?

Answer: Lucintel forecasts that service will remain the larger segment over the forecast period due to increasing public knowledge of various treatment options, including tailored medications.

Q7. In hemato oncology testing market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to the increased prevalence of multiple myeloma, lymphoma, and leukemia, along with the availability of cutting-edge medical facilities and healthcare, as well as the introduction of new technology.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the hemato oncology testing market by technology (PCR, IHC, NGS, cytogenetics, and others), cancer type (leukemia, lymphoma, myeloproliferative neoplasms, and other), product (assay kits and reagents and services), end use (hospitals, academic & research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Hemato Oncology Testing Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Hemato Oncology Testing Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Hemato Oncology Testing Market by Technology
    • 3.3.1: PCR
    • 3.3.2: IHC
    • 3.3.3: NGS
    • 3.3.4: Cytogenetics
    • 3.3.5: Others
  • 3.4: Global Hemato Oncology Testing Market by Cancer Type
    • 3.4.1: Leukemia
    • 3.4.2: Lymphoma
    • 3.4.3: Myeloproliferative Neoplasms
    • 3.4.4: Other
  • 3.5: Global Hemato Oncology Testing Market by Product
    • 3.5.1: Assay Kits and Reagents
    • 3.5.2: Services
  • 3.6: Global Hemato Oncology Testing Market by End Use
    • 3.6.1: Hospitals
    • 3.6.2: Academic & Research Institutes
    • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Hemato Oncology Testing Market by Region
  • 4.2: North American Hemato Oncology Testing Market
    • 4.2.1: North American Hemato Oncology Testing Market by Product: Assay Kits and Reagents and Services
    • 4.2.2: North American Hemato Oncology Testing Market by End Use: Hospitals, Academic & Research Institutes, and Others
  • 4.3: European Hemato Oncology Testing Market
    • 4.3.1: European Hemato Oncology Testing Market by Product: Assay Kits and Reagents and Services
    • 4.3.2: European Hemato Oncology Testing Market by End Use: Hospitals, Academic & Research Institutes, and Others
  • 4.4: APAC Hemato Oncology Testing Market
    • 4.4.1: APAC Hemato Oncology Testing Market by Product: Assay Kits and Reagents and Services
    • 4.4.2: APAC Hemato Oncology Testing Market by End Use: Hospitals, Academic & Research Institutes, and Others
  • 4.5: ROW Hemato Oncology Testing Market
    • 4.5.1: ROW Hemato Oncology Testing Market by Product: Assay Kits and Reagents and Services
    • 4.5.2: ROW Hemato Oncology Testing Market by End Use: Hospitals, Academic & Research Institutes, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Hemato Oncology Testing Market by Technology
    • 6.1.2: Growth Opportunities for the Global Hemato Oncology Testing Market by Cancer Type
    • 6.1.3: Growth Opportunities for the Global Hemato Oncology Testing Market by Product
    • 6.1.4: Growth Opportunities for the Global Hemato Oncology Testing Market by End Use
    • 6.1.5: Growth Opportunities for the Global Hemato Oncology Testing Market by Region
  • 6.2: Emerging Trends in the Global Hemato Oncology Testing Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Hemato Oncology Testing Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Hemato Oncology Testing Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: F. Hoffmann-La Roche
  • 7.2: Abbott
  • 7.3: EntroGen
  • 7.4: Qiagen
  • 7.5: Cepheid
  • 7.6: Thermo Fisher Scientific
  • 7.7: Bio-Rad Laboratories
  • 7.8: Illumina
  • 7.9: Amoy Diagnostics
  • 7.10: ArcherDX